AnaptysBio, Inc. (ANAB)

In the past six months, AnaptysBio's stock price has experienced significant appreciation. The company reported strong fourth-quarter 2025 financial results, with EPS of $1.58 and revenue of $108.25 million. AnaptysBio announced a strategic plan to spin off its biopharma operations into a new public entity, First Tracks Biotherapeutics. The Board of Directors authorized a stock repurchase plan of up to $100 million of its outstanding common stock. Several investment firms upgraded analyst ratings and increased price targets for AnaptysBio. The strong commercial performance of its partnered drug Jemperli and progress on imsidolimab positively impacted investor sentiment. Insiders have been active sellers of the stock.

AnaptysBio's product demand is not typically subject to significant seasonality. The demand for its products, once commercialized, would be driven by the prevalence of the diseases they treat and the efficacy and safety profile of the treatments. The company's revenue is currently almost entirely from collaboration revenue, which is tied to the commercial success of its partners' products and the achievement of clinical and regulatory milestones. Its financial performance is more influenced by clinical trial outcomes, regulatory approvals, and partner sales rather than seasonal fluctuations in patient demand.

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. The company operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Preparation Manufacturing industry, advancing its own pipeline candidates and generating revenue from out-licensed antibodies through collaborations. Key products and pipeline candidates include Rosnilimab, ANB033, ANB101, Jemperli (dostarlimab-gxly), and Imsidolimab.

AnaptysBio, Inc. is based in San Diego, California, and focuses on delivering immunology therapeutics in the United States. The company leverages partnerships with larger drugmakers like GSK and Vanda Pharmaceuticals to facilitate the global commercialization of its programs, enabling access to global markets.

AnaptysBio's brand reputation in the past year appears to be largely positive, driven by strong clinical trial data and strategic business decisions. The company has received positive feedback regarding rosnilimab's Phase 2b data in rheumatoid arthritis. The planned spin-off of its biopharma operations is also seen as a move to unlock and amplify value for investors. Analyst ratings are generally favorable, with a consensus "Buy" rating. However, there have been past events that impacted its reputation, such as a securities class action lawsuit filed in March 2020. Within the past year, the discontinuation of the ulcerative colitis trial for rosnilimab due to not meeting primary or key secondary endpoints could be a minor negative event.

AnaptysBio, Inc. has a significant institutional ownership presence, with 184 institutional owners holding a total of 28,505,925 shares. Major institutional owners include EcoR1 Capital, LLC, Point72 Asset Management, L.P., BlackRock, Inc., Vanguard Group Inc, Tang Capital Management LLC, State Street Corp, Morgan Stanley, Sanofi, Millennium Management Llc, and D. E. Shaw & Co., Inc. Major individual owners include Oleg Nodelman, Avalon Ventures VII L P, Holdings A. Novo, and Frazier Healthcare VII LP.